stoxline Quote Chart Rank Option Currency Glossary
  
Allogene Therapeutics, Inc. (ALLO)
3.51  0.01 (0.29%)    04-17 16:00
Open: 3.57
High: 3.58
Volume: 2,507,826
  
Pre. Close: 3.5
Low: 3.455
Market Cap: 594(M)
Technical analysis
2024-04-17 4:44:53 PM
Short term     
Mid term     
Targets 6-month :  5.2 1-year :  5.96
Resists First :  4.45 Second :  5.11
Pivot price 3.99
Supports First :  3.39 Second :  2.82
MAs MA(5) :  3.67 MA(20) :  4.07
MA(100) :  3.76 MA(250) :  4.15
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  6.3 D(3) :  6.6
RSI RSI(14): 30.4
52-week High :  6.88 Low :  2.23
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ALLO ] has closed above bottom band by 9.1%. Bollinger Bands are 9.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.59 - 3.61 3.61 - 3.63
Low: 3.4 - 3.43 3.43 - 3.45
Close: 3.46 - 3.51 3.51 - 3.55
Company Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Headline News

Wed, 17 Apr 2024
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - Defense World

Mon, 15 Apr 2024
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat

Mon, 15 Apr 2024
SG Americas Securities LLC Buys Shares of 53484 Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Sun, 14 Apr 2024
Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Movies Canada

Tue, 09 Apr 2024
Allogene Therapeutics Announces Q2 Investor Conference Participation - Investor Relations | Allogene Therapeutics

Sat, 16 Mar 2024
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 169 (M)
Held by Insiders 1.11e+008 (%)
Held by Institutions 22.4 (%)
Shares Short 25,010 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.0029e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 163 %
Return on Assets (ttm) 475 %
Return on Equity (ttm) -26.9 %
Qtrly Rev. Growth 95000 %
Gross Profit (p.s.) 0
Sales Per Share -69.39
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -238 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -2.5
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 0.92
Stock Dividends
Dividend 0
Forward Dividend 3.062e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android